Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vincent Rajkumar

Showing results (431-440 of 602) with videos related to

Pageof 61
Sort By:
Blood|March 25, 2021
Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myelomaThierry Facon, Christopher P Venner, Nizar J Bahlis, et al.
Annals of Medicine|March 9, 2017
Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognitionEli Muchtar, Angela Dispenzieri, Martha Q Lacy, et al.
Blood Cancer Journal|December 18, 2019
Mate pair sequencing outperforms fluorescence in situ hybridization in the genomic characterization of multiple myelomaJames Smadbeck, Jess F Peterson, Kathryn E Pearce, et al.
Mayo Clinic Proceedings|October 8, 2016
Systemic Immunoglobulin Light Chain Amyloidosis-Associated Myopathy: Presentation, Diagnostic Pitfalls, and OutcomeEli Muchtar, Daniele Derudas, Michelle Mauermann, et al.
British Journal of Haematology|July 13, 2017
Elevation of serum lactate dehydrogenase in AL amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantationEli Muchtar, Angela Dispenzieri, Martha Q Lacy, et al.
American Journal of Hematology|November 25, 2021
Characteristics and risk factors for thrombosis in POEMS syndrome: A retrospective evaluation of 230 patientsPatrick W Mellors, Taxiarchis Kourelis, Ronald S Go, et al.
Genetics in Medicine Open|December 13, 2024
Disparity in the detection of chromosome 15 centromere in patients of African ancestry with a plasma cell neoplasmAlaa Koleilat, Hongwei Tang, Neeraj Sharma, et al.
American Journal of Hematology|July 8, 2023
Natural history, predictors of development of extramedullary disease, and treatment outcomes for patients with extramedullary multiple myelomaSaurabh Zanwar, Matthew Ho, Yi Lin, et al.
Leukemia & Lymphoma|May 18, 2019
Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myelomaPatrick W Mellors, Moritz Binder, Francis K Buadi, et al.
Blood|April 17, 2012
Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trialShaji K Kumar, Suzanne R Hayman, Francis K Buadi, et al.
Pageof 61

Showing results (431-440 of 602) with videos related to

Sort By:
Pageof 61
Blood|March 25, 2021
Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myelomaThierry Facon, Christopher P Venner, Nizar J Bahlis, et al.
Annals of Medicine|March 9, 2017
Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognitionEli Muchtar, Angela Dispenzieri, Martha Q Lacy, et al.
Blood Cancer Journal|December 18, 2019
Mate pair sequencing outperforms fluorescence in situ hybridization in the genomic characterization of multiple myelomaJames Smadbeck, Jess F Peterson, Kathryn E Pearce, et al.
Mayo Clinic Proceedings|October 8, 2016
Systemic Immunoglobulin Light Chain Amyloidosis-Associated Myopathy: Presentation, Diagnostic Pitfalls, and OutcomeEli Muchtar, Daniele Derudas, Michelle Mauermann, et al.
British Journal of Haematology|July 13, 2017
Elevation of serum lactate dehydrogenase in AL amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantationEli Muchtar, Angela Dispenzieri, Martha Q Lacy, et al.
American Journal of Hematology|November 25, 2021
Characteristics and risk factors for thrombosis in POEMS syndrome: A retrospective evaluation of 230 patientsPatrick W Mellors, Taxiarchis Kourelis, Ronald S Go, et al.
Genetics in Medicine Open|December 13, 2024
Disparity in the detection of chromosome 15 centromere in patients of African ancestry with a plasma cell neoplasmAlaa Koleilat, Hongwei Tang, Neeraj Sharma, et al.
American Journal of Hematology|July 8, 2023
Natural history, predictors of development of extramedullary disease, and treatment outcomes for patients with extramedullary multiple myelomaSaurabh Zanwar, Matthew Ho, Yi Lin, et al.
Leukemia & Lymphoma|May 18, 2019
Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myelomaPatrick W Mellors, Moritz Binder, Francis K Buadi, et al.
Blood|April 17, 2012
Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trialShaji K Kumar, Suzanne R Hayman, Francis K Buadi, et al.
Pageof 61